The effect of Nanocurcumin on liver fibrosis
- Conditions
- iver fibrosis.
- Registration Number
- IRCT20210427051098N2
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
patients between 30 and 70 years of age with liver fibrosis F=2 referring to the liver and digestive consultation and treatment clinic
History of alcohol intake or current intake of alcohol
evidence of other forms of chronic and acute liver diseases (such as viral hepatitis B, C etc), biliary disease, known autoimmune hepatitis and hereditary disorders affecting the liver (storage disease of iron, copper etc)
current pregnancy or breastfeeding
Use of hepatotoxic medication
current Lung and kidney disease
Drug abuse, history of cancer
Treatment with anti-inflammatory, corticosteroids and hormones medication
Use of weight loss medication or diets
Intolerance or allergy to the supplement
Unwillingness to participate in the study
New diet
Changes in the patient's medications
Patients with current warfarin medications
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver fibrosis. Timepoint: Before and 16 weekes after the intervention. Method of measurement: Determining the amount of liver tissue fibrosis by using Elastography (2D Shear Wave Elastography- SWE).;Liver steatosis. Timepoint: Before and 16 weekes after the intervention. Method of measurement: Determining the amount of liver tissue steatosis by using Elastography (2D Shear Wave Elastography- SWE).
- Secondary Outcome Measures
Name Time Method